Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 26-29 November 2012

Four new safety referrals evaluated as impact of new legislation kicks in

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) held its fifth meeting from 26-29 November 2012.
At the meeting, the PRAC started a review of four medicines that are nationally authorised in EU Member States. The Committee also evaluated evidence for new safety signals from EU reporting systems, assessed updated risk management plans for certain medicines and discussed a number of periodic safety update reports.

Since the PRAC’s first meeting in July 2012, fresh procedures have started under the new pharmacovigilance legislation. The increasing number of reviews for the PRAC, triggered by EU Member States, indicates that the legislation is working effectively and underlines that Member States view the PRAC as the effective mechanism for assessing all aspects of risk management for human medicines.
For an overview of all information available following the meeting of the PRAC, see the table below:
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/11/news_detail_001666.jsp&mid=WC0b01ac058004d5c1